Galvusmet Vidagliptin 50mg+ Metformin 850mg 1 Tablet [Prescription Required]

REMINDER: A doctor's prescription is required to purchase this product. To avoid delay in delivery or cancellation of your order(before the item is SHIPPED), please email a copy of your prescription (.jpeg or .pdf file format) to,OnlinePharmacy@watsons.com.ph,with your order number after Checkout. Our pharmacist will also get in touch with you to validate your prescription. Please be ready to show your original prescription upon claiming/delivery of your order.

Adjunct to diet & exercise to improve glycemic control in patients with type 2 DM as monotherapy. In combination with metformin/sulfonylurea (SU)/thiazolidinedione (TZD) alone when diet & exercise do not result in adequate glycemic control. In triple combination with SU & metformin when diet & exercise plus dual therapy do not provide adequate glycemic control. In combination with insulin (with or without metformin) when diet, exercise & stable dose of insulin do not result in adequate glycemic control. Initial combination with metformin in patients with type 2 DM whose diabetes is not adequately controlled by diet &amp, exercise alone

*This product is VAT-exempt. Price displayed is without VAT.

Place of Origin

Turkey

Product Usage

Should be taken with food.

Ingredients

Each tablet contains Vildagliptin 50 mg and Metformin hydrochloride 850 mg.

Warnings

Special precautions: Not be used in treatment of type 1 DM and diabetic ketoacidosis. Risk of lactic acidosis and hypoglycemia; may be temporarily withheld in case of loss of glycemic control. Risk of decreased vit B12 serum levels. Concomitant use with drugs affecting renal function or metformin HCl disposition. Pre-treatment ALT or AST >2.5 x ULN. Perform liver function test prior to treatment initiation at 3-mth intervals during the 1st yr and periodically thereafter. Avoid excessive alcohol intake. Discontinue use in case of hypoxemia; undergoing surgical procedure and radiologic studies involving intravascular administration of iodinated contrast materials. withdraw use if an increase in AST/ALT ≥3 x ULN and do not reinitiate. Monitor renal function. Hepatic and renal impairment. Pregnancy and lactation. Childn <18 yr. Elderly.

Width

1

Height

1

Depth

1